Advances in therapeutic approaches to ulcerative colitis and Crohn's disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) management has evolved significantly.
• Conventional therapies and biotherapies play crucial roles in IBD treatment.

Purpose of the Study:

• To review recent advances in conventional and biologic therapies for inflammatory bowel disease.
• To highlight the evolving goals and subspecialty nature of IBD management.

Main Methods:

• Review of literature on molecular mechanisms of conventional agents (azathioprine, thioguanosine triphosphate, mesalamine).
• Summary of advancements in biotherapy, including monoclonal antibodies, small molecules, and cell-gene therapy.
• Discussion of treatment objectives beyond pharmacotherapy.

Main Results:

• Conventional agents show progress in understanding molecular mechanisms for monitoring and chemoprevention.
• Biotherapy advancements include new monoclonal antibodies (e.g., infliximab, adalimumab), antisense oligonucleotides, and cell-gene therapies.
• IBD management emphasizes remission induction, side effect limitation, disease modification, and complication avoidance.

Conclusions:

• The landscape of inflammatory bowel disease treatment is expanding with novel therapeutic options.
• Effective IBD management requires a comprehensive approach beyond drug therapy, focusing on patient outcomes.
• The complexity and cost of biotherapy are contributing to the emergence of IBD as a distinct subspecialty.